For Maisel et al. [70], NT-proBNP predicts the risks of death or CHF in asymptomatic patients and may be used as a complementary test in the evaluation of such risks and the short-term follow-up to CHF treatments. The gene discussed is NPPB; the disease is congestive heart failure.